Broker sees 'strong asymmetric upside risk' for ResMed shares

Goldman Sachs is recommending investors snap up this beaten down share.

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have really taken a beating in recent months.

Concerns over the emergence of obesity drugs have weighed heavily on sentiment.

But has this all been a huge overreaction? The team at Goldman Sachs appears to believe that this is the case and is urging investors to snap up the company's shares while they're dirt cheap.

What is Goldman Sachs saying?

Goldman notes that semaglutide (branded as Ozempic, Rybelsus or Wegovy) and tirzepatide (branded as Mounjaro) belong to a class called GLP-1/GIP-receptor agonists.

While these drugs were initially targeting type 2 diabetes, they have consistently demonstrated clear efficacy in weight management and cardiovascular indications.

Given that obstructive sleep apnoea (OSA) is "an indication that is correlated with weight and cardiovascular comorbidities," the broker acknowledges that there are concerns about the impact these drugs could have on demand for ResMed's industry-leading technology.

However, its research shows that the two treatments can grow strongly together over the long term. Particularly given that "OSA remains under-penetrated, with global estimates suggesting <20% and many countries well-below this level."

The base case for ResMed

Goldman has outlined its base case for ResMed in a world with obesity drugs. It explains:

Our base scenario adopts our base case obesity forecasts from above (i.e. -7% reduction in obese or overweight with comorbidity population by 2030E). It then assumes the following patient retention on CPAP (mild 55%; moderate 70%; severe 80%). In this scenario we could see only a modest benefit of AHI [Apnea-Hyponea Index] in GPI-2 over GPI-1, which could result in a lower level of patients.

Overall, we expect continued adoption/success of the GLP-1/GIP class to reduce the OSA population addressable by CPAP, but the impact to RMD/FPH is mitigated by: i) long-term market share gains from competitors; and ii) continued improvements in OSA diagnosis rates (potentially catalysed by the GLP-1/GIP class itself).

ResMed shares have 'strong asymmetric upside'

Goldman highlights that its analysts "see strong asymmetric upside risk from current levels."

According to the note, the broker has reiterated its buy rating on ResMed's shares with a reduced price target of $33. This implies a potential upside of almost 53% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Why I think this ASX small-cap stock is a bargain at 40 cents

Here’s why this business has a compelling outlook...

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

2 ASX 200 biotech stocks announcing big news today

Let's see how the market has responded to these announcements.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Healthcare Shares

This ASX 200 stock is rocketing 17% after announcing a $300m special dividend

A huge dividend is expected to be paid to investors in the near future.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

CSL shares haven't been this cheap in 9 years: Time to buy?

Analysts think big returns could be on offer from this biotech giant.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Bell Potter names the best ASX healthcare stocks to buy now

The broker has good things to say about these stocks.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Two ASX healthcare companies that are using AI to leverage their business

Interested in adding healthcare stocks integrating artificial intelligence to your portfolio? Here are two to consider. 

Read more »